For researchers who find that compounded semaglutide is not working as expected, the issue may be sourcing related (degraded product, inaccurate fill weights) or protocol related (insufficient dose, dietary factors)
Researchers are also investigating whether GLP-1 therapies may improve conditions such as fatty liver disease, kidney disease, sleep apnea, and chronic inflammation
Defy Medical evaluates each patient individually, so we encourage you to book a consultation and discuss concerns directly with your provider
This is always the same
More recently, in March 2024, Wegovy was This approval followed promising results from novo Nordisks SELECT trial, which followed 17,604 adults with obesity or overweight and cardiovascular disease but no history of diabetes